Everolimus + bicalutamide in treatment of CRPC?

A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …

What to do with a man with M0 or M1 disease who is progressing on treatment

Is the addition of enzalutamide (Xtandi) to an LHRH agonist now the appropriate standard of care for a man with M0 or M1 prostate cancer who starts to progress on treatment with an LHRH agonist alone? … READ MORE …

Reduction in prostate size prior to permanent seed prostate brachytherapy

Data from a randomized clinical trial have shown that there is more than one way to reduce the size of a man’s prostate (if such cytoreduction is needed) prior to treatment with permanent, radioactive pellets (permanent, low-dose brachytherapy) for localized prostate cancer. … READ MORE …

STRIVE trial again shows benefits to enzalutamide vs. bicalutamide

Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Combining a TKI with bicalutamide in men with CRPC

We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date. … READ MORE …

A “last word” from the Genitourinary Cancers Symposium

Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE

Preliminary results of RTOG 96-01 in progressive prostate cancer

RTOG 96-01 is a randomized, multi-center Phase III trial designed to compare bicalutamide monotherapy + salvage radiation therapy  to a placebo + salvage radiation alone in men with pT2-3N0Mo prostate cancer who have an elevated PSA after surgery. … READ MORE …

Sexual orientation and impact of androgen deprivation therapy

An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others. … READ MORE …

High-dose bicalutamide as second-line hormone therapy in CRPC patients

Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH agonist). … READ MORE …

Does ADT3 really work? The TARP study

A number of physicians and patients have believed for years that so-called “triple” androgen blockade (ADT3) is a more effective option than an LHRH alone or combined androgen deprivation in the treatment of men with advanced prostate cancer. However, the clinical evidence supporting this belief has been limited. … READ MORE …

Managing the side effects of bicalutamide monotherapy

In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients. … READ MORE …

Generic bicalutamide now available in the USA

According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.

Prostate cancer news reports: Friday, May 8, 2009

In today’s news reports we address such issues as:

  • The possibility that type of initial treatment and comorbidities explain at least some racial disparities in prostate cancer survival
  • Failure of time to surgery to explain racial disparities in post-treatment outcome
  • Once-weekly bicalutamide as a regimen to prevent prostate cancer … READ MORE …

Friday’s news reports: March 27, 2009

The reports addressed today offer information from three very technical studies dealing with:

  • Genomic profiling of localized prostate cancers among African American men
  • “DNA licensing” and prostate cancer progression
  • Interleukin-6 over-expression and bicalutamide resistance … READ MORE …